Written question asked by Andrew Rosindell (Conservative) on Thursday, 1 December 2022, in the House of Commons. It was due for an answer on Monday, 5 December 2022. It was answered by Will Quince (Conservative) on Friday, 23 December 2022 on behalf of the Department of Health and Social Care.
Teplizumab
- Question
-
To ask the Secretary of State for Health and Social Care, whether he has had discussions with his counterpart in the United States on Teplizumab; and (b) what stage Teplizumab is at in the licensing process.
- Answer
-
The Medicines and Healthcare products Regulatory Agency is unable to provide the information requested as it is commercially sensitive.
Secondary information
- Type
- Written question
- Reference
- 100904
- Session
- 2022-23
- Subjects
- Diabetes USA Teplizumab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-12-23 14:58:17 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/100904
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/100904
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/100904